Managing HIV disease after Delta

Publisher Website
Google Scholar
Abstract
Delta (conducted by a European/Australian group coordinated by Britain's Medical Research Council and the Agence National de Recherches sur le SIDA in France) and ACTG175 (conducted in the United States by the AIDS Clinical Trials Group of the National Institutes of Health) have recently released their main findings. They were large randomised double blind placebo controlled trials of zidovudine (AZT) monotherapy versus combinations of zidovudine and didanosine (ddI) or zidovudine and zalcitabine (ddC) with an additional limb of didanosine monotherapy in ACTG175. Both used clinical end points, and ACTG175 also used changes in CD4 cell count. Both recruited patients who had not previously been exposed to nucleosides (Delta 2124 patients, ACTG175 1067 patients) and symptomatic patients who had previously received nucleosides (Delta 1083 patients including patients with AIDS, CD4 count 50-350; ACTG175 1400 patients excluding patients with AIDS, CD4 count 200-500.)